🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    phase 3 mab completed

    1 trial

  2. Aflibercept 8 mg

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  3. Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  4. Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

    Regeneron UK Limited

    Macular Edema Secondary to Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  5. Aglatimagene besadenovec + valacyclovir

    Candel Therapeutics

    Prostate Cancer

    phase 3 mab active

    1 trial

  6. Albutein 50 g/l solución para perfusión.

    Instituto Grifols S.A.

    Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization

    phase 3 small molecule active

    1 trial

  7. Alecensa 150 mg hard capsules, VINORELBINE, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin ACTAVIS 10 mg/ml concentrat pentru soluţie perfuzabilă, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Alecensa 150 mg hard capsules

    Hoffmann-La Roche

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  8. Alectinib - Usual

    Lxo Ireland Designated Activity Company

    ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  9. Aliskiren

    Novartis Pharmaceuticals

    Acute Decompensated Heart Failure

    phase 3 small molecule completed

    1 trial

  10. Almonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer Metastatic

    phase 3 small molecule active

    1 trial

  11. Alogliptin and glimepiride

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  12. Alogliptin and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  13. Ambrisentan Viatris 5 mg film-coated tablets, Placebo de AMBRISENTAN VIATRIS 5 mg - composition: cellulose microcristalline; lactose monohydraté; silice colloïdale anhydre; stéarate de magnésium (vegetable origin); opadry II 85G94065 PINK; eau purifiée, TADALAFIL

    Pari Pharma GmbH

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  14. Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day

    Ultragenyx UK Limited

    Sanfilippo Syndrome

    phase 3 small molecule active

    1 trial

  15. Amchafibrin

    Lxo Ireland Designated Activity Company

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  16. Amisulpride, DEXAMETHASONE PHOSPHATE, ONDANSETRON

    Lacuna Pharma Pty Ltd

    post-operative nausea and vomiting in pediatric patients

    phase 3 small molecule active

    1 trial

  17. Amlitelimab, Amlitelimab, -, -, -, Amlitelimab

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  18. Amlitelimab, Placebo, -, TACROLIMUS , PIMECROLIMUS , Amlitelimab

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  19. Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

    Sanofi-aventis Healthcare Pty Ltd

    atopic dermatitis

    phase 3 small molecule active

    1 trial

  20. Amlodipine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Essential Hypertension

    phase 3 small molecule active

    1 trial

  21. Amlodipine

    United Therapeutics Europe Ltd

    Depression

    phase 3 small molecule active

    1 trial

  22. Amyvid 1900 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Trontinemab, Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, [18F]MK-6240

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

    phase 3 small molecule active

    1 trial

  23. Anagrelide Hydrochloride

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  24. Anakinra 100mg and Placebo Depo-Medrone

    United Therapeutics Europe Ltd

    Gout

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources